Sign in

    Gonzalo Artiach Castanon

    Research Analyst at Danske Bank

    Gonzalo Artiach Castanon is an Analyst-Equity at Danske Bank A/S, specializing in pharmaceutical and biotech equity research with a focus on Nordic-listed companies such as Vicore Pharma Holding and Boule Diagnostics. He has contributed to performance research supporting investment decisions and provided detailed financial analysis, with his prior reports at ABG Sundal Collier AB demonstrating deep sectoral expertise and accuracy in earnings forecasts. Starting his analyst career at ABG Sundal Collier AB in 2021 before moving to Danske Bank in early 2024, he holds advanced academic credentials including a doctorate from Karolinska Institutet. While specific securities licenses or FINRA registrations are not publicly listed, his research is referenced in institutional investment coverage and analyst certification documents.

    Gonzalo Artiach Castanon's questions to ASTRAZENECA (AZN) leadership

    Gonzalo Artiach Castanon's questions to ASTRAZENECA (AZN) leadership • Q4 2024

    Question

    Gonzalo Artiach Castanon of Danske Bank inquired about launch expectations for Datroway in the TROPION-Breast01 setting, considering ADC sequencing with Enhertu. He also asked about the market opportunity for baxdrostat in primary aldosteronism.

    Answer

    David Fredrickson, EVP of Oncology, outlined that Datroway addresses a clear need in the fourth-line plus HR-positive setting and complements Enhertu, creating treatment options across the HER2 spectrum, including for patients post-ADC. Ruud Dobber, EVP of BioPharmaceuticals, noted that while primary aldosteronism is highly underdiagnosed, it represents a significant unmet need, affecting an estimated 5-8% of hypertensive patients.

    Ask Fintool Equity Research AI

    Gonzalo Artiach Castanon's questions to ASTRAZENECA (AZN) leadership • Q2 2024

    Question

    Gonzalo Artiach Castanon asked for an update on FDA interactions for Dato-DXd ahead of its PDUFA date and sought a hypothesis for why Truqap failed in a triple-negative breast cancer study despite a strong launch in its approved indication.

    Answer

    EVP, Oncology R&D, Susan Galbraith, stated that discussions with the FDA for Dato-DXd are ongoing with no new updates. Regarding Truqap, she explained its mechanism is most effective where there is a reciprocal relationship with endocrine signaling, which is present in its approved indication and in prostate cancer, but not in the same way in triple-negative breast cancer. EVP, Oncology Business Unit, David Fredrickson, confirmed Truqap's launch is strong due to rapid biomarker adoption and good tolerability.

    Ask Fintool Equity Research AI